Latest News and Press Releases

Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to continue in the first quarter and throughout 2022 ...

Delay in publication of the Audited Results due to immaterial technical audit matters The Company expects the Audited Results will not differ from announced preliminary results NEW YORK and TORONTO...

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record fiscal year 2021 revenue and Adjusted...

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record fiscal year 2021 revenue and Adjusted...

Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET NEW YORK, TORONTO, and HERZLIYA, Israel, April ...

NEW YORK, TORONTO, and HERZLIYA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that...

NEW YORK and TORONTO, and HERZLIYA, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) and Clever Leaves...

NEW YORK, TORONTO, and HERZLIYA, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that...

The partnership will focus on the new CBD wellness market in Israel Israeli Minister of Health announced yesterday that CBD will be removed from the Dangerous Drugs Act Altman Health...

Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market Acquisition is Expected to be Accretive Strengthen InterCure’s Position as the Largest Cannabis Company Outside...